Flammulina velutipes

Other Names

Agaricus atropesAgaricus fuscipesAgaricus nigripesAgaricus sphinxAgaricus velutipesAgaricus velutipes var. atropesAgaricus velutipes var. fuscipesAgaricus velutipes var. rubescensAgaricus velutipes var. rufipesAgaricus velutipes var. sphinxCollybia eriocephalaCollybia lacteaCollybia veluticepsCollybia velutipesCollybia velutipes f. aestivalisCollybia velutipes f. curtaCollybia velutipes f. microsporaCollybia velutipes var. albaCollybia velutipes var. lacteCollybia velutipes var. spongiosaDongguEnokiEnokidakeEnokitakeEnoko-takeFlammulina velutipes (Curtis) P.Karst.Flammulina velutipes var. lacteaFutuGolden needle mushroomGymnopus velutipesJīngūJīnzhēngūLily mushroomMyxocollybia velutipesNấm kim châmPaengi beoseotPleurotus velutipes var. lacteusVelvet footVelvet shankVelvet stemWild enokiWinter mushroom

Synopsis

Identity: Botanical and Chemical Classification

Taxonomic Identity and Nomenclature

Flammulina velutipes, also named golden needle mushroom, winter mushroom, and enokitake, is ascribed to the division Eumycota, subdivision Basidiomycotina, class Hymenomycetes, order Agaricales, family Tricholomataceae, genus Flammulina. The scientific name Flammulina translates to "flame-colored," while the words "veluti" + "pes" mean "foot covered with fine hair." Originally named Agaricus velutipes by Moses Ashley Curtis, it was renamed in 1947 by Rolf Singer.

A significant taxonomic revision has affected how this mushroom is understood commercially and scientifically. Flammulina species were recently reorganized thanks to DNA testing; a 2018 DNA analysis determined that the Asian variety is actually genetically separate, and that consequently the cultivated enoki mushroom is not Flammulina velutipes but rather a distinct species. Technically, the wild and cultivated enoki mushroom in Asia is now designated Flammulina filiformis. Recent research has identified genetic diversity and differentiation associated with geography, such that Asian enoki mushrooms were proposed to represent this second species, F. filiformis, while F. velutipes in Europe is used to produce velvet shank or velvet foot mushrooms with potentially different growth conditions. Despite this reclassification, a large portion of the scientific literature — including most biomedical research — continues to refer to the cultivated Asian mushroom under the name Flammulina velutipes, and the two names are commonly treated as synonymous in pharmacological contexts.

Common Names

Known as enokitake (榎茸), enokidake, or simply enoki in Japanese, these long, thin white mushrooms are used in East Asian cuisines including those of China, Japan, Vietnam, and Korea. They are cultivars also known by the name golden needle mushroom or lily mushroom. In Mandarin, the mushroom is called jinzhengu, meaning "golden needle mushroom." In British usage, the wild species is more commonly called velvet shank or velvet foot.

Physical Characteristics

Scientifically known as Flammulina velutipes, the mushroom is characterized by its long, thin stems and small caps. Often found in clusters, enoki mushrooms have a mild, subtly sweet flavor and a crunchy texture. Commercially, it is cultivated year-round in controlled indoor environments under low light and restricted airflow, producing the characteristic long, slender, pale-white fruiting bodies sold in markets worldwide. Wild specimens develop darker, shorter caps and are ecologically distinct from the elongated cultivated form.

Natural Habitat

Flammulina filiformis (syn. Flammulina velutipes) is native to East Asia, growing wild on the stumps and dead wood of broadleaf trees such as elm, willow, and mulberry across China, Japan, and Korea, typically fruiting in cool autumn and winter months. In Europe, Flammulina velutipes is particularly common on dead elm trees, and is currently more often seen on ash, beech, and oaks, as well as occasionally on wood from other broadleaf trees.

Dosage Forms and Preparations

Owing to its high nutritional values and attractive taste, F. velutipes is one of the most popular edible mushrooms worldwide. It is available and consumed in multiple forms: fresh fruiting bodies used in cooking; dried and powdered fruiting bodies; standardized extracts (particularly polysaccharide-enriched or beta-glucan fractions); isolated or recombinantly produced proteins such as FIP-fve; and as mycelium-based preparations. The cultivation of enoki mushrooms began in Japan in the early 18th century, and their popularity has only grown since then, spreading to various parts of the world.

Traditional and Historical Use

Flammulina filiformis has been cultivated and consumed in China for over a thousand years, with historical records referencing jingu (golden mushroom) in classical Chinese materia medica texts, where it was prescribed to support liver and stomach function and reduce excessive internal heat.

In addition to their nutritional value, folk medicine has long recognized mushrooms for their wide spectrum of therapeutic and prophylactic uses. Many medicinal mushrooms are important ingredients in Traditional Chinese Medicine, including Flammulina velutipes. Appreciated for its health advantages, the enoki mushroom has been utilized in traditional Chinese and Japanese medicine for hundreds of years as a tonic for liver disease, high cholesterol levels, stomach ailments, and high blood pressure.

It is a thin, white, elongated mushroom that has been native to Japan for millennia and has been cultivated there for more than three centuries. Enoki has traditionally been used in Japan, China, and Korea to make soups. Like most mushrooms, it was first harvested and then cultivated.

The primary traditional preparations across East Asia included fresh or dried mushroom incorporated into soups, broths, and decoctions. Historically, it has been valued for its delicate flavor and purported health benefits, particularly in Chinese and Japanese cultures where it was incorporated into soups, salads, and medicinal decoctions. Traditional uses explicitly separated it as both a culinary staple and a medicinal preparation, with the medicinal forms typically being hot-water decoctions of the fruiting body.

Key Constituents and Active Compounds

General Composition

Many bioactive constituents from a range of chemical families have been isolated from different parts of the mushroom, including carbohydrates, proteins, lipids, glycoproteins, phenols, and sesquiterpenes. The mushroom is full of thiamin, niacin, potassium, riboflavin, pantothenic acid, calcium, copper, iron, and selenium, and is low in dietary cholesterol and sodium. It is rich in vitamin B1 and contains traces of zinc.

Polysaccharides

Polysaccharides are widely regarded as the primary pharmacologically active constituents of F. velutipes. Research has shown that polysaccharides are one of the main active components of F. velutipes, possessing various bioactivities such as antioxidative, immunomodulatory, anti-inflammatory, liver protection, anti-tumor, and anti-hyperlipidemia effects.

Multiple distinct polysaccharide fractions have been isolated and characterized:

FVP2C, identified using FTIR, HPLC, NMR spectroscopy, methylation analysis, and GC-MS, is composed of glucose, galactose, mannose, and fucose in a molar ratio of 100:14:7:4. With a molecular weight of 27.3 × 10³ Da, it was characterized as an alpha-D-(1→4)-glucan that is highly branched with alpha-D-(1→6)-glucosyl residues, with a single galactose or small amounts of mannoses and fucose at the C-6 position every twelve residues, on average, along the main chain.
FVPB2 was identified as a homogeneous heteropolysaccharide with a molecular weight of approximately 1.50 × 10⁴ Da, containing D-galactose, D-mannose, L-fucose, and D-glucose at a molar ratio of 1.9:1.2:1:2.5.
FVP1 was characterized as a homogeneous polysaccharide with a relative molecular weight of 54.78 kDa, composed of mannose (7.74%), glucose (70.41%), and galactose (16.38%).
An alkaline-soluble antitumor polysaccharide was prepared from the cell wall of F. velutipes, whose backbone is mainly composed of beta-(1→3)-D-linked glucose, with a molecular weight estimated to be approximately 200 kD.
The crude polysaccharide FVP-C from the water extract, and its main purified component FVP-S1, was found to be an acidic polysaccharide consisting of glucuronic acid, xylose, and glucose.

Proteins and Glycoproteins

The fungal immunomodulatory protein FIP-fve, mainly extracted from the fruiting body of F. velutipes, has been studied extensively and explored for its diverse bioactivities including immunomodulatory, anticancer, and anti-inflammatory properties.

Proflamin was isolated from the culture mycelium of F. velutipes by means of ion exchange column chromatography and molecular sieving. It is a weakly acidic glycoprotein containing more than 90% protein and less than 10% carbohydrate, with a molecular weight of 13,000 ± 4,000.

Ribosome-inactivating proteins such as flammin, velin, velutin, and flammulin are present in the fruiting bodies and extracts of the mushroom. Studies have also reported isolation of proteins such as hemagglutinin — which has mitogenic and antiproliferative functions — ice-binding proteins, and flammutoxin, a cytolysin.

Low-Molecular-Weight Compounds

Nine chemical constituents have been isolated and identified from the fruiting bodies: D-arabinitol, 9(Z) oleic acid, 9(Z),12(Z) linoleic acid, ergosta-5,7,22-trien-3β-ol, 5α,8α-epidioxy-ergosta-6,22-dien-3β-ol, 3β,5α,9α-trihydroxy-ergosta-7,22-dien-6-one, 5-hydroxymethyl-2-(1-methyl-ethenyl)-1-cyclohexanol, 1,3-dilinolein, and hemisceramide. D-arabinitol may serve as a marker compound for processed golden needle mushroom products quality control.

Key phenolic compounds identified include α-linolenic acid, γ-linolenic acid, 2,5-dihydroxybenzaldehyde, protocatechuic acid ethyl ester, and ferulic acid. Phenolic acids and a flavonoid have been identified from the substrate of F. velutipes, specifically ferulic acid, ρ-coumaric acid, vanillic acid, 3-methoxygallic acid, and tricin.

The total dietary fiber content in Flammulina velutipes powder (FVP) is approximately 29.34 mg/100 g, and the total mycosterol content is 46.57 ± 0.37 mg/100 g.

Mechanisms of Action

Immunomodulatory Mechanisms

FVP-1 increased the secretion of cytokines (including TNF-α, IL-6, and IL-1β) and their mRNA expression, upregulated the transcription and translation of COX-2 and iNOS, and enhanced the release of reactive oxygen species and phagocytic activity in macrophages, thereby promoting the maturation and transformation of certain lymphocytes. The RSAD2 effector was involved in the immunomodulatory function of FVP-1 towards macrophages and mouse splenocytes, through mediating FVP-1's activation and regulation of the NF-κB/MAPK signaling pathway.

Three FVPs were found to induce a significant increase in cellular nitric oxide formation, interleukin-1 production, and tumor necrosis factor-alpha secretion in macrophages in vitro, and their immuno-modulating activity was dose-dependent.

Antitumor Mechanisms

Since 1995, F. velutipes polysaccharides (FVP) have been found to be effective against solid tumors, and their anti-tumor activity has been shown to be mediated by the tumor-bearing host. Mechanistically, FVP reversed IL-4-induced M2-polarization by activating the TLR4/NF-κB axis, and in vitro assays confirmed the expression of pro-inflammatory genes and antitumor effects of the polysaccharide.

Proflamin exhibited no cytocidal effect against cultured cell lines in vitro, suggesting that its antitumor activity is indirect and host-mediated rather than directly cytotoxic. Similar to FIP-fve, the antitumor effects of EA6, which are manifested by virtue of strengthening specific and innate immunity, were shown to be mediated by CD4+ T cells.

Lipid Metabolism Mechanisms

Dietary fiber, as an active polysaccharide component of F. velutipes, cannot be decomposed by lytic enzyme or digested in the human alimentary tract. This water-soluble dietary fiber can be combined with cholesterol or cholic acid by adsorption, reducing the amount of cholic acid returned to the liver and increasing the metabolism of cholesterol and its transformation into cholic acid. The cholesterol concentration is thereby reduced and the absorption of lipids in the small intestine is disturbed, reducing the lipid content in blood.

Intervention with the polysaccharide FVPB1 significantly increased the mRNA expression of Lcat and Cyp7a1 enzymes while markedly reducing the transcriptional level of Hmgcr reductase. Low concentrations of FVPB1 enhanced CYP7A1 protein expression, whereas medium and high concentrations promoted LCAT protein expression.

Anti-inflammatory Mechanisms

Studies have demonstrated that various extracts, polysaccharides, and structurally diverse compounds exhibit multifaceted biological activities, including antioxidant, immunomodulatory, anti-inflammatory, antibacterial, hepatoprotective, antihyperlipidemic, antitumor, and gut microbiota-regulating effects, often through the modulation of multiple signaling pathways, such as NF-κB, MAPK/ERK1/2, Keap1/Nrf2, TLR4/NF-κB, and PI3K/AKT.

FIP-fve suppresses RSV-induced inflammation via inhibiting NF-κB translocation.

Scientific Evidence by Area of Use

1. Immunomodulation

This is among the most extensively investigated pharmacological areas for F. velutipes constituents. The evidence is primarily preclinical (in vitro and animal models), with no robust controlled clinical trials in humans published to date.

In vitro and animal evidence: In vitro immunomodulatory studies showed the polysaccharide FVPB2 induced proliferation of mouse spleen lymphocytes in a dose-dependent manner. The levels of IgM and IgG secreted by B cells increased after FVPB2 treatment. FVP1 (1000 mg/mL) possessed significant immune activity by increasing the secretion of nitric oxide (NO), tumour necrosis factor-α (TNF-α) at 3183 ± 133.84 pg/mL, interleukin (IL)-6 at 1133.21 ± 39.05 pg/mL, and IL-12 at 579.96 ± 74.53 pg/mL in macrophages. Bioactivity tests in vitro indicated that the polysaccharide FVPA1 could significantly enhance natural killer cell activity against K562 tumor cells.

Evidence strength: Preliminary. All immunomodulatory findings come from cell culture and rodent experiments. Current evidence indicates therapeutic potential of F. velutipes in both in vitro and in vivo models; however, further research is required, particularly in clinical applications and elucidating molecular mechanisms.

2. Antitumor / Anticancer Activity

This area has been investigated since the early 1970s and includes work with multiple distinct fractions.

Polysaccharides (EA3, EA5, EA6, FVP): From F. velutipes (enokitake), high antitumor activity has been documented, and polysaccharides and a low molecular weight protein-bound polysaccharide (EA6) were isolated. EA6 was demonstrated to be active against tumors when administered orally, but not as effective by intraperitoneal injection. It proved to be especially useful orally in combination with surgery and other antitumor agents. The chemical structure of EA3 was found to be that of a beta-(1→3)-glucan.

Proflamin (preclinical): The antitumor effect of proflamin was studied with murine tumors. It was markedly effective against the syngeneic tumors B-16 melanoma and adenocarcinoma 755. At a dose of 10 mg/kg orally, the increases in median survival time of mice with B-16 and Ca-755 were 86 and 84%, respectively. When given as combination therapy along with vaccines or surgery, proflamin also inhibited the growth of sarcoma S-180, L1210 leukemia ascite cells, and Meth-A fibrosarcoma.

In vitro cell line evidence: Subfractions of FVP have exhibited anti-proliferation activity against human gastric cancer BGC-823 cells, lung cancer A549 cells, and murine melanoma B16F10 cells in vitro. Glycoproteins found in the fruiting body and mycelium of F. velutipes also exhibit anticancer effects. Proflamin, an acidic glycoprotein isolated from the mycelium, enhanced several immunosuppression processes and exhibited antiproliferative effects against various cancer cells.

Epidemiological observation: An epidemiology survey of Flammulina velutipes (enokitake) farmers in Japan found that the mushroom farmers had lower rates of cancer deaths than people who were not involved in mushroom farming. This finding is observational and cannot establish causation.

Evidence strength: Preliminary to moderate for preclinical models; no confirmed human clinical trial evidence. All antitumor data are from animal models, cell lines, or epidemiological associations. The preclinical findings are substantial but human translation has not been demonstrated.

3. Lipid Metabolism and Cardiovascular Effects

Animal model evidence: According to the literature, Flammulina velutipes contains biologically active components such as dietary fiber, polysaccharide, and mycosterol, whose effects in reducing blood sugar, blood pressure, and cholesterol have been reported. A study used active components extracted from F. velutipes powder (FVP) and F. velutipes extract (FVE) to investigate the impact on lipid metabolism of hamsters. The heteropolysaccharide FVPB1 demonstrated efficacy in inhibiting lipid accumulation in Raw264.7 cells and zebrafish, as well as in reducing weight gain and ameliorating liver injury in high-fat diet-induced mice. High concentrations of FVPB1 significantly increased serum ApoA1 levels, while all tested doses reduced serum ApoB levels in mice.

Dynamic changes of gut microbiota mediated by Flammulina velutipes polysaccharide (FVP) could effectively regulate lipid metabolism in high fat diet-fed obese mice. FVP administration resulted in lower bile acids content in plasma of obese mice, and qRT-PCR analysis showed FVP could relieve cholestasis in obese mice through altering bile acids metabolic pathways and changing related gene expressions in mice liver and ileum.

Evidence strength: All current lipid-related evidence is from animal and cell-based studies. No human clinical trials have demonstrated lipid-lowering effects of standardized F. velutipes extracts at reported doses.

4. Gut Microbiota Modulation

FVP exhibits many biological activities; the effects on gut microflora and metabolism were explored via in vitro fermentation using human fecal inoculums, which allowed investigation of the influence of FVP on human gut microflora composition and metabolites. Alpha and beta diversity analyses demonstrated that a high-fat diet induced substantial dysbiosis in gut microbiota of mice, characterized by reduced microbial diversity and richness. Intervention with FVPB1 significantly modulated the structural composition of the intestinal microbiota in high-fat diet-fed mice, exerting its lipid-lowering effect in part by ameliorating gut microbiota dysbiosis.

Evidence strength: Preliminary. Gut microbiota modulation data derive from in vitro fermentation and rodent studies. Human gut microbiome intervention trials are lacking.

5. Hepatoprotective Effects

A carbon tetrachloride-induced acute liver injury mouse model was used to study the regulation of gut microbiota and the hepatoprotective effect of polysaccharides from F. velutipes (FVPs). The hepatoprotective effect of FVPs led to reduced levels of serum aspartate transaminase (AST), alanine aminotransferase (ALT), triglyceride (TG), total cholesterol (TC), total bile acid (TBA) content, and change in liver histopathology. Their anti-oxidant activity was exhibited by decreased levels of hepatic malonaldehyde (MDA) and protein carbonyl (PC) content and increased catalase (CAT) and superoxide dismutase (SOD) content.

Polysaccharide FVP1 showed significant hepatitis B surface antibody (anti-HBV) activity through reducing the expression of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA replication, suggesting a novel role for FVP1 as an immunomodulator in dietary supplements to prevent HBV infection.

Evidence strength: Preliminary. All hepatoprotective data come from animal injury models. No human studies on liver protection from F. velutipes supplementation have been identified in the peer-reviewed literature.

6. Allergic Airway Disease and Anti-inflammatory Effects

FIP-fve has been the subject of several preclinical investigations in allergy and respiratory inflammation models.

FIP-fve is a fungal immunomodulatory protein (FIP) isolated from Flammulina velutipes that exhibits anti-inflammatory properties. In studies investigating whether FIP-fve affects house dust mite-induced asthma and inflammation, oral FIP-fve decreased dust mite-induced airway hyperresponsiveness, airway inflammation, cell infiltration, and expression of cytokines in the bronchoalveolar lavage fluid of BALB/c mice.

Oral FIP-fve also decreased RSV-induced airway hyperresponsiveness (AHR), airway inflammation, and IL-6 expression in bronchoalveolar lavage fluid of BALB/c mice. FIP-fve inhibited viral titers on plaque assay and Western blot, as well as inhibited RSV-stimulated expression of IL-6 on ELISA and RT-PCR, suggesting that FIP-fve decreases RSV replication, RSV-induced inflammation, and respiratory pathogenesis.

In a murine model of obesity-associated allergic asthma, body weight, serum metabolic parameters (cholesterol, glucose, ALT), airway hyperresponsiveness (AHR), serum cytokine profiles, and lung histopathology were evaluated. FIP-fve treatment significantly reduced HFD-induced body weight gain and normalized serum cholesterol, glucose, and ALT levels.

FIP-fve has been demonstrated to skew the immune response toward Th1 cytokine production. Studies investigated whether oral administrations of FIP-fve inhibited allergen-induced chronic airway inflammation in a mouse asthma model.

Evidence strength: All FIP-fve respiratory data are from preclinical murine models. No human clinical trials evaluating FIP-fve for allergy or asthma have been identified in the peer-reviewed literature.

7. Antioxidant Activity

The polysaccharide FVP I-A obtained from Flammulina velutipes possessed antioxidant activity and could enhance non-specific and specific immune responses in vitro. In an acute liver injury model, FVP anti-oxidant activity was reflected by decreased levels of hepatic malonaldehyde (MDA) and protein carbonyl (PC) content and increased catalase (CAT) and superoxide dismutase (SOD) content. Antioxidant assessments have relied primarily on DPPH radical scavenging, superoxide anion scavenging, and reducing power assays — standard in vitro methodologies. Evidence in humans is absent.

8. Antiviral Activity

Polysaccharide FVP1 showed significant hepatitis B surface antibody activity through reducing the expression of HBsAg, HBeAg, and HBV DNA replication. These results suggest a novel role for FVP1 to be applied as an immunomodulator in dietary supplements to prevent HBV infection. This finding is in vitro only and requires clinical validation.

Body Systems and Health Areas Associated with Flammulina velutipes

Immune system: Demonstrated immunomodulatory activities through multiple mechanisms, including enhancement of macrophage function, NK cell activity, and lymphocyte proliferation.
Gastrointestinal system and gut microbiome: Polysaccharides from F. velutipes have been reported to possess anti-inflammatory, antioxidant, immune modulatory, and intestinal flora-regulating properties.
Cardiovascular and lipid metabolism: Anti-atherosclerotic and thrombosis inhibition activity, as well as antihypertensive and cholesterol-lowering effects, have been demonstrated in preclinical studies.
Hepatic (liver) system: FVPs have been reported to have hepatoprotective effects in the context of acute liver injury models.
Respiratory system: FIP-fve has been shown in murine models to modulate airway hyperresponsiveness and reduce inflammatory cytokine profiles in allergic airway disease.
Oncology (supportive/experimental): Bioactive compounds such as polysaccharides and proflamin demonstrate immunomodulatory and potential anti-tumor properties in in vitro and animal studies, and may enhance the activity of natural killer (NK) cells and promote anti-tumor immune responses.
Neurological (memory and cognition): Preclinical data suggest an ability to aid in restoring memory and overcoming learning deficits, though these findings require substantial human validation.

Dosage Forms and Reported Dosages

There is no universally established clinical dosage for F. velutipes extracts or isolated compounds. The following are dosages specifically reported in cited studies:

Proflamin was studied at a dose of 10 mg/kg orally in mice, producing increases in median survival time of 86% (B-16 melanoma) and 84% (adenocarcinoma 755).
In B cell immunomodulation studies, FVPB2 was tested at 200 μg/mL, with ERK1/2 or NF-κB inhibitors used at 50 μg/mL.
FVP1 was tested at a concentration of 1000 mg/mL for immune cytokine secretion in macrophage studies.
GLPH intervention at 100 mg/kg/day was studied in an acute liver injury mouse model, with outcomes measured including serum ALT, AST, ALP, and GGT levels.
The soluble dietary fiber fraction SE-SDF showed no toxicity in cell assays at concentrations of 200–800 μg/mL.

All reported dosages are from preclinical (animal or cell culture) experiments. No standardized human clinical dosing protocol has been established in the peer-reviewed literature reviewed for this article.

Safety Considerations

General Safety as a Food

The biological activity of F. velutipes can help reduce blood sugar, blood pressure, and cholesterol in addition to its antithrombotic effects. It has no known toxic effect on the human body and is considered very beneficial to human health. This general assessment applies to the mushroom consumed as food in normal dietary amounts.

Listeria monocytogenes Contamination

The most significant documented safety concern associated with F. velutipes is not intrinsic toxicity but rather microbial contamination. Consumption of L. monocytogenes-contaminated enoki mushrooms has been associated with multistate human listeriosis cases, affecting 30 patients and causing four deaths over a three-year period in the United States (as of 2024 CDC data). The first known listeriosis outbreak linked to enoki mushrooms, imported from the Republic of Korea, occurred from 2016 to 2020, with 48 ill people identified from the United States and Canada, leading to a coordinated response by the U.S., Canada, France, and Australia.

Listeria monocytogenes can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy persons may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea, infection can cause miscarriages and stillbirths among pregnant women.

Although enoki mushrooms are customarily cooked in East Asian cuisine, publicly available recipes for English-speaking consumers suggest that consumers in North America may be eating these mushrooms raw. Thorough cooking eliminates L. monocytogenes risk.

Intrinsic Toxicity Concerns

Infectious material can be present in mushrooms, especially if eaten raw or inadequately cooked, as illustrated by multiple Listeria monocytogenes infections with four deaths due to the consumption of enoki mushrooms in the USA. Published literature has also noted preclinical data on potential cardiotoxic and myotoxic effects of wild Flammulina velutipes in mice; however, the clinical relevance of such findings for cultivated mushroom consumed as food or supplement is unclear and requires further investigation.

Immune-Stimulating Potential

FIP-fve demonstrates several kinds of biological activities including anti-allergy, anti-tumor, and immunomodulation. Given this immune-modulating profile, individuals with autoimmune conditions or those taking immunosuppressive medications represent a theoretical group for whom caution is warranted, though direct clinical interaction data are not available in the peer-reviewed sources reviewed here.

Polysaccharide Fraction Safety

A polysaccharide fraction was found to be non-toxic by brine shrimp assay. When injected into mice intraperitoneally, this polysaccharide triggered proliferation of splenic lymphocytes and also a vascular dilation and hemorrhage (VDH) response — a finding relevant to parenteral administration but of uncertain significance for oral supplementation.

Overall Evidence Assessment

Current evidence indicates the therapeutic potential of F. velutipes in both in vitro and in vivo models. However, further research is required, particularly in clinical applications and in elucidating molecular mechanisms. The body of research on F. velutipes is extensive at the preclinical level, spanning immunology, oncology, lipid metabolism, gut microbiology, and respiratory medicine. However, as of the time of this writing, no large-scale, randomized, controlled human clinical trials have been identified that definitively establish therapeutic efficacy for any specific health condition at a defined supplemental dose. The compounds from F. velutipes have demonstrated various biological activities including antitumour and anticancer activities, anti-atherosclerotic and thrombosis inhibition activity, antihypertensive and cholesterol-lowering effects, anti-aging and antioxidant properties, and ability to aid with restoring memory and overcoming learning deficits. This mushroom is not only a great source of nutrients but also possesses tremendous potential in pharmaceutical drug development. The translation of these preclinical findings into human therapeutic applications remains an active and promising but as yet incomplete area of scientific investigation.

References

Health Conditions

Health conditions that Flammulina velutipes may help support.

No conditions available.

Body Systems

Body systems that Flammulina velutipes may help support.

No body systems available.